Verve-102 Gene-Editing Therapy Shows Promising LDL Cholesterol Reduction in Early Trial

The therapy achieved up to 53% LDL cholesterol reduction without serious side effects, advancing toward Phase 2 trials in late 2025.

Initial Phase 1b trial data for Verve-102 demonstrated significant LDL cholesterol reductions, with a maximum reduction of 69% in some patients.
The therapy targets the PCSK9 gene in the liver, using an improved lipid nanoparticle delivery system developed in-house to address prior safety concerns.
All 14 trial participants tolerated the treatment well, with no serious adverse events or significant laboratory abnormalities reported.
The U.S. FDA recently granted Fast Track designation to Verve-102, recognizing its potential to address hyperlipidemia and cardiovascular risks.
Verve plans to begin Phase 2 trials in the second half of 2025, with ongoing collaboration with Eli Lilly on global development and commercialization.